JP2014502955A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502955A5
JP2014502955A5 JP2013534894A JP2013534894A JP2014502955A5 JP 2014502955 A5 JP2014502955 A5 JP 2014502955A5 JP 2013534894 A JP2013534894 A JP 2013534894A JP 2013534894 A JP2013534894 A JP 2013534894A JP 2014502955 A5 JP2014502955 A5 JP 2014502955A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013534894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502955A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/001787 external-priority patent/WO2012054084A2/en
Publication of JP2014502955A publication Critical patent/JP2014502955A/ja
Publication of JP2014502955A5 publication Critical patent/JP2014502955A5/ja
Pending legal-status Critical Current

Links

JP2013534894A 2010-10-20 2011-10-19 抗体 Pending JP2014502955A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40509010P 2010-10-20 2010-10-20
US61/405,090 2010-10-20
PCT/US2011/001787 WO2012054084A2 (en) 2010-10-20 2011-10-19 Antibodies

Publications (2)

Publication Number Publication Date
JP2014502955A JP2014502955A (ja) 2014-02-06
JP2014502955A5 true JP2014502955A5 (enExample) 2014-12-11

Family

ID=45975790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013534894A Pending JP2014502955A (ja) 2010-10-20 2011-10-19 抗体

Country Status (15)

Country Link
US (2) US20130259878A1 (enExample)
EP (1) EP2629796A4 (enExample)
JP (1) JP2014502955A (enExample)
KR (1) KR20130138802A (enExample)
CN (1) CN103534268B (enExample)
AU (1) AU2011318574B2 (enExample)
BR (1) BR112013009551A2 (enExample)
CA (1) CA2815041A1 (enExample)
EA (1) EA201300470A1 (enExample)
IL (1) IL225571A0 (enExample)
MX (1) MX2013004476A (enExample)
NZ (1) NZ610091A (enExample)
SG (1) SG189835A1 (enExample)
WO (1) WO2012054084A2 (enExample)
ZA (1) ZA201302459B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616382A (en) 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
RU2648141C2 (ru) * 2012-09-19 2018-03-22 Эббви Биотерапьютикс Инк. Способы идентификации антител с пониженной иммуногенностью
WO2017120557A1 (en) * 2016-01-09 2017-07-13 Arbele Limited Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
SG10201800265UA (en) * 2016-06-17 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MA50102A (fr) 2017-11-14 2020-07-15 Univ Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
US12410234B2 (en) 2018-04-26 2025-09-09 The Trustees Of The University Of Pennsylvania Compositions and methods for retrieving tumor-related antibodies and antigens
RU2703949C1 (ru) * 2018-04-27 2019-10-22 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены
US20210116456A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Compositions and methods for diagnosis and treatment of cancer
WO2019222428A1 (en) * 2018-05-16 2019-11-21 Arbele Limited Composition of bispecific antibodies and method of use thereof
US20250270314A1 (en) * 2021-08-02 2025-08-28 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
CN118119847A (zh) * 2021-10-08 2024-05-31 泰贝乐医疗科技有限公司 用于检测cdh17的方法和组合物
WO2024100294A1 (en) 2022-11-11 2024-05-16 Ospedale San Raffaele S.R.L. Cdh17 car
CN120917040A (zh) * 2023-01-31 2025-11-07 毕格哈特生物科学公司 抗cdh17抗体及其用途
EP4669672A1 (en) * 2023-02-23 2025-12-31 Hansoh Bio LLC ANTIBODIES, ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE
JP2026518758A (ja) * 2023-05-24 2026-06-09 マルティテュード・セラピューティクス・インコーポレイテッド 抗体及びその抗体薬物複合体
KR20260082360A (ko) * 2023-09-22 2026-06-04 레푸 바이오파마 컴퍼니 리미티드 항-cdh17 항체 및 이의 용도
CN120230211A (zh) * 2023-12-29 2025-07-01 广东菲鹏制药股份有限公司 抗cdh17抗体或其抗原结合片段及其应用
TW202547885A (zh) * 2024-04-30 2025-12-16 中國商蘇州宜聯生物醫藥有限公司 抗體、抗體藥物偶聯物及其用途
TW202613168A (zh) * 2024-05-20 2026-04-01 大陸商杭州中美華東製藥有限公司 抗cdh17抗體、其抗體藥物偶聯物及其用途
WO2025242100A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技(成都)有限公司 针对cdh17的抗体及其用途
TW202613172A (zh) * 2024-05-31 2026-04-01 大陸商江蘇先聲生物製藥有限公司 抗cdh17抗體、綴合物及其應用
WO2025252211A1 (zh) * 2024-06-07 2025-12-11 映恩生物制药(苏州)有限公司 抗人cdh17抗体
WO2026067602A1 (zh) * 2024-09-26 2026-04-02 上海翰森生物医药科技有限公司 一种含抗体药物偶联物的药物组合物及其用途
WO2026090578A1 (en) * 2024-10-25 2026-04-30 Antharis Therapeutics Inc. Cdh17-binding antibodies and methods of use thereof
CN120554510B (zh) * 2025-05-29 2026-05-12 吉林大学 抗钙粘蛋白-17的双表位抗体及采用其制备的抗体药物偶联物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
WO1996040942A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Humanized antibodies to e-selectin
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
WO2002057316A1 (en) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン2抗体と機能性核酸の使用
US7615529B2 (en) * 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
US8535677B2 (en) * 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
WO2009116670A1 (ja) * 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010095461A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規モノクローナル抗体、並びにその使用
US8647623B2 (en) * 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
NZ616382A (en) * 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17

Similar Documents

Publication Publication Date Title
JP2011046732A5 (enExample)
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
JP2020502271A5 (enExample)
RU2014120629A (ru) Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака
JP2015534577A5 (enExample)
JP2016502515A5 (enExample)
JP2018070648A5 (enExample)
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
JP2020536109A5 (enExample)
NZ705848A (en) Anti-cd38 antibodies
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
RU2012154339A (ru) НОВОЕ АНТИТЕЛО ПРОТИВ c-Met
JP2014503189A5 (enExample)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
RU2016122041A (ru) Новые анти-клаудин антитела и способы их применения
RU2014109039A (ru) Биспецифические антигенсвязывающие молекулы
RU2010145177A (ru) Лекарственное средство для лечения рака печени
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2010531140A5 (enExample)
JP2010526028A5 (enExample)
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2014530215A5 (enExample)